ADMA Biologics (ADMA) Receiving Somewhat Positive News Coverage, Accern Reports
Media coverage about ADMA Biologics (NASDAQ:ADMA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ADMA Biologics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.8356195049453 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- $6.86 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter (americanbankingnews.com)
- BIOTEST AG : ex-dividend day for annual dividend (4-traders.com)
- -$0.51 Earnings Per Share Expected for ADMA Biologics Inc (ADMA) This Quarter (americanbankingnews.com)
- ADMA: Second Quarter 2017 Financial Results and Corporate Update (finance.yahoo.com)
ADMA has been the subject of several research reports. Maxim Group set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a report on Monday, May 15th. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
ADMA Biologics (NASDAQ:ADMA) traded down 0.58% on Friday, hitting $3.43. 30,342 shares of the company’s stock traded hands. The stock has a 50-day moving average of $3.29 and a 200-day moving average of $3.99. The stock’s market cap is $88.47 million. ADMA Biologics has a one year low of $2.67 and a one year high of $7.70.
ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.29. ADMA Biologics had a negative net margin of 198.99% and a negative return on equity of 791.24%. The company had revenue of $3.40 million during the quarter, compared to analyst estimates of $3.52 million. On average, equities analysts forecast that ADMA Biologics will post ($1.94) earnings per share for the current fiscal year.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Stock Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related stocks with our FREE daily email newsletter.